

# A study of compliance of directly observed short course therapy for tuberculosis at tertiary care hospital

Sanjay Dattu Mahajan<sup>1\*</sup>, Dipak Onkar Patil<sup>2</sup>

<sup>1,2</sup> Assistant Professor, Department of TB and Chest, Dr Ulhas Patil Medical College and Hospital, Jalgaon, Maharashtra, INDIA.

Email: [drmahajansd@gmail.com](mailto:drmahajansd@gmail.com)

## Abstract

**Introduction:** Tuberculosis (TB) has been declared a global public health emergence by the World Health Organization (WHO). The disease causes significant mortality and morbidity globally and with the advent of the human immune deficiency virus (HIV) epidemic, TB is regarded as a world-wide public health challenge. The rising incidence of TB due to the effect of HIV in both developed and developing countries is well recognized, besides well-known risk factors, the most important unresolved challenge in TB control is the treatment completion. **Aims and Objective:** To study the Compliance of DOTs therapy and reasons of the non-compliance. **Methodology:** This is a cross-sectional, hospital based study of The all the patients taking treatment under Dots Centre of tertiary health care during March 2013 to March 2014. There were 220 patients of all category are taking treatment at this DOT Centre of tertiary health Centre. Based on above two definitions patients were divided into two groups Compliance and Non-compliance. All the necessary information was collected by pre-testes, semi-structured questionnaire. Chi-square test used by statistical analysis calculated by Graph Pad Prism-5. **Result:** Out of the 220 patients 132 were non-compliant so, Overall Non-Compliance was 60.00%. Proportion of Non-Compliance was more in Male i.e. (67.90%) as compared to Female i.e. (37.93%) this observed difference was highly significant ( $P < 0.0001$ ,  $X^2 = 15.98$ ; Highly significant). Proportion of Non-Compliance was more in Poor Socio Economic Status, Middle Socio Economic Status as compared to Upper Socio Economic Status i.e. 67.00%, 35.00% and 30.00% respectively this observed difference was highly significant ( $P < 0.0001$ ;  $X^2$  for trend = 16.76; highly Significant.). Most common reasons of the Non-compliance were H/O Side effects of DOTs therapy, On advise to stop by private physician, Dot Centre was not assessable to Patients, Relief from symptoms, Friends told to stop, Transfer for work to other place. **Conclusion:** The non-compliance in our study found to be 60% which is of much concern so the emphasis on the reasons of poor compliance; H/O Side effects of DOTs therapy, On advise to stop by private physician, Dot Centre was not assessable to Patients, Relief from symptoms, Friends told to stop, Transfer for work to other place should be noted to increase the compliance of the patient.

**Keywords:** Compliance, Non-Compliance, DOTs therapy.

## \*Address for Correspondence:

Dr. Sanjay Dattu Mahajan, Assistant Professor, Department of TB and Chest, Dr. Ulhas Patil Medical College & Hospital, N.H.No.6, Jalgaon-Bhusawal Road, Jalgaon, Khurd, Jalgaon-425309 Maharashtra, INDIA.

Email: [drmahajansd@gmail.com](mailto:drmahajansd@gmail.com)

Received Date: 18/06/2015 Revised Date: 23/07/2015 Accepted Date: 12/08/2015

## Access this article online

Quick Response Code:



Website:

[www.statperson.com](http://www.statperson.com)

DOI: 08 December  
2015

## INTRODUCTION

Tuberculosis (TB) has been declared a global public health emergence by the World Health Organization (WHO)<sup>1</sup>. The disease causes significant mortality and morbidity globally and with the advent of the human immune deficiency virus (HIV) epidemic, TB is regarded as a world-wide public health challenge (Kochi, 199; WHO, 1992)<sup>1</sup>. The rising incidence of TB due to the effect of HIV in both developed and developing countries is well recognized (Narainet *al*, 1992)<sup>2</sup> Besides well-known risk factors, the most important unresolved challenge in TB control is the treatment completion. Treatment will only be effective if the patient completes the regimen which includes a combination of drugs

recommended by the physicians. Poor compliance contributes to the worsening of the TB situation by increasing incidence and initiating drug resistance. Resistance to anti-TB drugs has also emerged as an important obstacle in the control of the disease. World-wide patient compliance with anti-TB therapy, with an estimate of as low as 40% in developing countries, remains the principle cause of treatment failure (Fox,1983)<sup>3</sup>. MDR-TB is essentially man-made phenomenon and arises due to inadequate treatment of drug-sensitive TB<sup>4</sup>. The prevalence of MDR-TB mirrors the functional state and efficacy of tuberculosis control programmes in the country. Previous treatment for TB is the strongest risk factor for development of MDR-TB<sup>5</sup>. Drug resistance is a major threat to tuberculosis (TB) control programs worldwide<sup>6</sup>. The critical aspect of management is ensuring compliance with a full course of chemotherapy (Cuneo and Snider, 1989)<sup>7</sup>. The World Health Organization recommends at least 85% cure rate of all diagnosed TB cases (WHO, 1992). In order to achieve this cure rate, compliance needs to be in the order of 85-90 % (Murray et al, 1990)<sup>8</sup>.

## AIMS AND OBJECTIVE

To study the Compliance of DOTs therapy and reasons of the non-compliance.

## MATERIAL AND METHODS

This is a cross-sectional, hospital based study of The all the patients taking treatment under Dots Centre of tertiary health care during March 2013 to March 2014. In this study the compliance and non-compliance to treatment was studied. As per WHO and ministry of health and welfare; Compliance: was defined as completion of prescribed treatment or as missing less than 25% of treatment within the specified duration. Non-compliance: was defined as missing more than 25% of treatment in a month i.e. missed more than one week injection (daily/intermittent) or missed more than one week for collection of oral drugs (known as defaulters) or defaulting for more than one month (known as abandoned treatment). The non-compliance group also included patients who defaulted the treatment and were later retrieved through any means i.e. home visits, letter, returned of own accord, etc (known as defaulter retrieval) or patients who abandoned treatment but were retrieved by bringing back or returned of his or her own accord for resumption of treatment (known as abandoned treatment retrieval). Non-compliance was identified by a registry, which was regularly updated and medical records were also checked for confirmation of non-compliance. There are 220 patients of all category are taking treatment at this DOT Centre of tertiary health Centre. Based on above

two definitions patients were divided into two groups Compliance and Non-compliance. All the necessary information was collected by pre-testes, semi-structured questionnaire. Chi-square test used by statistical analysis calculated by Graph Pad Prism-5.

## RESULTS

Out of the 220 patients 132 were non-compliant so, Overall Non-Compliance was 60.00%

**Table 1:** Distribution of the compliance of Patients as per Sex

Sex	Non-Compliance	Compliance	Total
Male	110 (67.90%)	52(32.09%)	162(100%)
Female	22(37.93%)	36(62.07%)	58(100%)
Total	132 (60.00%)	88(40.00%)	220 (100%)

$P < 0.0001$ ,  $X^2 = 15.98$ ; highly significant.

Proportion of Non-Compliance was more in Male i.e. (67.90%) as compared to Female i.e. (37.93%) this observed difference was highly significant ( $P < 0.0001$ ,  $X^2 = 15.98$ ; Highly significant)

**Table 2:** Distribution of the Compliance as per the Socio-Economic Status of the patients

Socio Economic Status	Non-Compliance	Compliance	Total
Upper	3(30.00%)	7(70.00%)	10(100%)
Middle	14 (35.00%)	26 (65.00%)	40(100%)
Poor	115 (67.00%)	55(32.35%)	170(100%)
Total	132 (60.00%)	88(40.00%)	220(100%)

$P < 0.0001$ ;  $X^2$  for trend = 16.76; highly Significant

Proportion of Non-Compliance was more in Poor Socio Economic Status, Middle Socio Economic Status as compared to Upper Socio Economic Status i.e. 67.00%, 35.00% and 30.00% respectively this observed difference was highly significant ( $P < 0.0001$ ;  $X^2$  for trend = 16.76; highly Significant.)

## DISCUSSION

Factors that have been reported as being associated with increased compliance by many studies were directly observed therapy (Feinstein *et al*, 1959; 1968<sup>9</sup>; Jonson and Freeman, 1972<sup>10</sup>; Stradling and Poole, 1970; Strong, 1970; Chaulet<sup>11</sup> *et al*, 1967; Albert *et al*, 1976<sup>12</sup>) and combined short-course regimen (WHO, 1991). On the other hand, factors that were found as being associated with poor compliance were HIV infection, poverty, increasing immigration (Barnes and Barrows, 1993<sup>13</sup>; Drucker *et al* 1994; Cantwell *et al*, 1994<sup>14</sup>; Brudney and Dobkin; 1991<sup>15</sup>), intravenous drug user status, alcoholics, unemployment (Brudney and Dobkin, 1991 a, b<sup>16</sup>; Ferrer *et al*, 1991<sup>17</sup>; Crespo *et al*; 1992<sup>18</sup>). In our study we have observed that Out of the 220 patients 132 were non-compliant so, Overall Non-Compliance was 60.00%.

Proportion of Non-Compliance was more in Male i.e. (67.90%) as compared to Female i.e. (37.93%) this observed difference was highly significant. ( $P < 0.0001$ ,  $X^2 = 15.98$ ; Highly significant). Proportion of Non-Compliance was more in Poor Socio Economic Status, Middle Socio Economic Status as compared to Upper Socio Economic Status i.e. 67.00%, 35.00% and 30.00% respectively this observed difference was highly significant ( $P < 0.0001$ ;  $X^2$  for trend = 16.76; highly Significant.). Most common reasons of the Non-compliance were H/O Side effects of DOTs therapy, On advise to stop by private physician, Dot Centre was not assessable to Patients, Relief from symptoms, Friends told to stop, Transfer for work to other place. These are confirmative with Nyi Nyi Naing *et al*<sup>19</sup>

## CONCLUSION

The non-compliance in our study found to be 60% which is of much concern so the emphasis on the reasons of poor compliance; H/O Side effects of DOTs therapy, On advise to stop by private physician, Dot Centre was not assessable to Patients, Relief from symptoms, Friends told to stop, Transfer for work to other place should be noted to increase the compliance of the patient.

## REFERENCES

1. Kochi A. The global tuberculosis situation and new control strategies of the World Health Organization. *Tubercle* 1991; 72: 1-6.
2. Narain JP, Raviglione MC, Kochi A. HIV- associated tuberculosis in developing countries: epidemiology and strategies for prevention. *Tuberc Lung Dis* 1992; 73: 311-21.
3. Fox W. Compliance of patients and physicians: a lesson from tuberculosis 2. *Br Med J* 1983; 287: 101-5
4. Sharma SK, Mohan A. Multidrug-resistant tuberculosis - a<sup>a</sup>. menace that threatens to destabilize tuberculosis control. *Chest* 2006; 130 ; 261-72.
5. Faustini A, Hall A, Perucci C. Risk factors for multi-drug<sup>5</sup>. resistant tuberculosis in Europe: a systematic review. *Thorax* 2006; 61: 158-63.
6. Zager EM, McNeerney R. Multidrug-resistant tuberculosis. *BMC Infect Dis* 2008; 8:1-15.
7. Cuneo WD, Snider DE. Enhancing patient compliance with tuberculosis therapy. *Clin Chest Me* 1989; 10: 375-80
8. Murray CJL, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. *Bull Tubercul Lung Dis* 1990; 65: 1-24
9. Feintein AR, Wood HF, Epstein JA, et al. A controlled study of three methods of prophylaxis against Streptococcal infection in a population of rheumatic children. II. Results of the first three years of study, including methods for evaluating the maintenance of oral prophylaxis. *N Engl J Med* 1959; 260: 697-702
10. Jonson DAW, Freeman H. Long-acting trans quillizers. *Practitioner* 1972; 208: 395-400 Stradling P, Poole GW. Twice weekly streptomycin plus isoniazid for tuberculosis. *Tubercle* 1970; 51: 44 -7
11. Chaulet P, Larbaoui D, Grosset J, et al. Intermittent chemotherapy with isoniazid and streptomycin in Algiers. *Tubercle* 1967; 48: 128-36.
12. Albert RK, Sbarbaro JA, Hudson LD, et al. High dose ethambutol: its role in intermittent chemotherapy, a six - year study. *Am Rev Respir Dis* 1976; 114: 699-704.
13. Barnes PF, Barrows SA. Tuberculosis in the 1990's. *Ann Intern Med* 1993; 119: 400-10
14. Cantwell MF, Snider DE, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. *JAMA* 1994; 272: 535-9
15. Brudney K, Dobkin J. A tale of two cities: tuberculosis control in Nicaragua and New York City. *Sem Respir Infect* 1991 a; 6: 261-72
16. Ferrer X, Krischbaum A, Toro J, et al. Compliance with tuberculosis treatment in adults in
17. Crespo R, Valdes L, Cayla JA. Difficulties in carry-ing out the treatment as seen by the tuberculous patient. *Atencion Primaria* 1992; 9: 260-2
18. NyiNyi Naing, Catherine D' Est, Abdul Rahman Isarosemi Salleh, Noraini Bakar And Mohd Robi Mahmod. Factors Contributing To Poor Compliance with Anti-Tb Treatment among Tuberculosis Patients. *Southeast Asian J Trop Med public health*. June 2001; 32 (2): 369-382.

Source of Support: None Declared  
Conflict of Interest: None Declared